- Home
- WOLF vs PRTA Comparison
WOLF vs PRTA Comparison
Compare WOLF & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOLF
- PRTA
- Stock Information
- Founded
- WOLF 1987
- PRTA 2012
- Country
- WOLF United States
- PRTA Ireland
- Employees
- WOLF N/A
- PRTA N/A
- Industry
- WOLF Semiconductors
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- WOLF Technology
- PRTA Health Care
- Exchange
- WOLF Nasdaq
- PRTA Nasdaq
- Market Cap
- WOLF 978.5M
- PRTA 809.8M
- IPO Year
- WOLF 1993
- PRTA N/A
- Fundamental
- Price
- WOLF $2.47
- PRTA $9.20
- Analyst Decision
- WOLF Hold
- PRTA Buy
- Analyst Count
- WOLF 15
- PRTA 9
- Target Price
- WOLF $13.15
- PRTA $54.57
- AVG Volume (30 Days)
- WOLF 30.1M
- PRTA 572.3K
- Earning Date
- WOLF 04-30-2025
- PRTA 05-07-2025
- Dividend Yield
- WOLF N/A
- PRTA N/A
- EPS Growth
- WOLF N/A
- PRTA N/A
- EPS
- WOLF N/A
- PRTA N/A
- Revenue
- WOLF $776,600,000.00
- PRTA $135,157,000.00
- Revenue This Year
- WOLF N/A
- PRTA N/A
- Revenue Next Year
- WOLF $27.27
- PRTA $131.71
- P/E Ratio
- WOLF N/A
- PRTA N/A
- Revenue Growth
- WOLF N/A
- PRTA 47.92
- 52 Week Low
- WOLF $2.06
- PRTA $9.10
- 52 Week High
- WOLF $30.86
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- WOLF 36.02
- PRTA 26.58
- Support Level
- WOLF $2.08
- PRTA $9.30
- Resistance Level
- WOLF $2.89
- PRTA $10.45
- Average True Range (ATR)
- WOLF 0.33
- PRTA 0.81
- MACD
- WOLF 0.00
- PRTA -0.15
- Stochastic Oscillator
- WOLF 37.61
- PRTA 2.77
About WOLF Wolfspeed Inc.
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).